Magle Chemoswed Holding AB (SE:MAGLE)
:MAGLE
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr3.94 - kr30.00
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr86.73M
Enterprise Valuekr419.32M
Total Cash (Recent Filing)kr13.59M
Total Debt (Recent Filing)kr346.19M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.49
Shares Outstanding20,649,378
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-11.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr377.00M
Bulls Say, Bears Say
Bulls Say
Business Model & Industry ExposureMagle’s core business—contract development (formulation/process) and manufacturing—creates recurring project and manufacturing revenue streams tied to pharmaceutical development cycles. This service-oriented model provides durable demand from drug sponsors and helps diversify revenue across projects and customers over the medium term.
Meaningful Equity CushionAs of 2025 the company retains a sizable equity base versus debt, offering a capital buffer to absorb operational shocks and support continued operations or restructuring. That equity headroom increases medium-term resilience and provides optionality for funding R&D or converting contracts into manufacturing scale.
Historical Revenue Expansion And Gross ProfitMagle delivered strong revenue growth through 2022–2024 and maintained high absolute gross profit, indicating underlying commercial and margin capability. This track record shows the business can scale revenue and preserve gross margins, a structural advantage if it stabilizes execution and returns to growth.
Bears Say
Two-year Negative Cash GenerationSustained negative operating and free cash flow over the last two years materially increases funding dependence and limits internal financing for capex, R&D, or working capital. Over a 2–6 month horizon this structural cash weakness raises refinancing risk and constrains strategic flexibility if losses continue.
Profitability Deterioration And VolatilityThe 2025 decline in revenue and sharp swing to negative EBIT demonstrates higher earnings volatility and weaker operating leverage. If this erosion persists, it impairs the company’s ability to fund growth internally and undermines confidence in stable margin recovery over the medium term.
Rising Leverage And Shrinking Equity CushionAlthough equity remains meaningful, rising debt and a shrinking equity cushion reduce financial flexibility and raise solvency risk if operating losses continue. Increased leverage makes the firm more sensitive to cash-flow stress and could necessitate dilutive or costly financing solutions.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr3.94 and its highest was kr30.00 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr86.73M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is May 18, 2026 which is in 42 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Mar 27, 2026. The company reported -kr6.491 earnings per share for the quarter, missing the consensus estimate of N/A by -kr6.491.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 20,649,378 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr6.491 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.042%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―